View Item 

Show simple item record

A Cost-Utility Analysis of Secondary Prophylaxis for Variceal Hemorrhage
dc.contributor.authorRubenstein, Joel H.en_US
dc.contributor.authorEisen, Glenn M.en_US
dc.contributor.authorInadomi, John M.en_US
dc.date.accessioned2010-06-01T18:33:28Z
dc.date.available2010-06-01T18:33:28Z
dc.date.issued2004-07en_US
dc.identifier.citationRubenstein, Joel H.; Eisen, Glenn M.; Inadomi, John M. (2004). "A Cost-Utility Analysis of Secondary Prophylaxis for Variceal Hemorrhage." The American Journal of Gastroenterology 99(7): 1274-1288. <http://hdl.handle.net/2027.42/71763>en_US
dc.identifier.issn0002-9270en_US
dc.identifier.issn1572-0241en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/71763
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=15233665&dopt=citationen_US
dc.format.extent186525 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Science Incen_US
dc.rights2004 by the Am. Coll. of Gastroenterologyen_US
dc.titleA Cost-Utility Analysis of Secondary Prophylaxis for Variceal Hemorrhageen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelInternal Medicine and Specialtiesen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDivision of Gastroenterology, University of Michigan Health System, Ann Arbor, Michigan; and Division of Gastroenterology, Oregon Health Sciences University, Portland, Oregonen_US
dc.identifier.pmid15233665en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/71763/1/j.1572-0241.2004.04153.x.pdf
dc.identifier.doi10.1111/j.1572-0241.2004.04153.xen_US
dc.identifier.sourceThe American Journal of Gastroenterologyen_US
dc.identifier.citedreferenceBernard B, Lebrec D, Mathurin P, et al. Beta-adrenergic antagonists in the prevention of gastrointestinal rebleeding in patients with cirrhosis: A meta-analysis. Hepatology 1997; 25: 63 – 70.en_US
dc.identifier.citedreferenceGarden OJ, Mills PR, Birnie GG, et al. Propranolol in the prevention of recurrent variceal hemorrhage in cirrhotic patients: A controlled trial. Gastroenterology 1990; 98: 185 – 90.en_US
dc.identifier.citedreferenceGraham DY, Smith JL. The course of patients after variceal hemorrhage. Gastroenterology 1981; 80: 800 – 9.en_US
dc.identifier.citedreferenceD'Amico G, Luca A. Natural history. Clinical-haemodynamic correlations. Prediction of the risk of bleeding. Bailliere's Clin Gastroenterol 1997; 11: 243 – 55.en_US
dc.identifier.citedreferenceEl-Serag HB, Everhart JE. Improved survival after variceal hemorrhage over an 11-year period in the Department of Veterans Affairs. Am J Gastroenterol 2000; 95: 3566 – 73.en_US
dc.identifier.citedreferenceChalasani N, Kahi C, Francois F, et al. Improved patient survival after acute variceal bleeding: A multicenter, cohort study. Am J Gastroenterol 2003; 98: 653 – 9.en_US
dc.identifier.citedreferenceGrace ND. Diagnosis and treatment of gastrointestinal bleeding secondary to portal hypertension. Am J Gastroenterol 1997; 92: 1081 – 91.en_US
dc.identifier.citedreferenceBernard B, Lebrec D, Mathurin P, et al. Propranolol and sclerotherapy in the prevention of gastrointestinal rebleeding in patients with cirrhosis: A meta-analysis. J Hepatol 1997; 26: 312 – 24.en_US
dc.identifier.citedreferenceLaine L, Cook D. Endoscopic ligation compared with sclerotherapy for treatment of esophageal variceal bleeding. A meta-analysis. Ann Intern Med 1995; 123: 280 – 7.en_US
dc.identifier.citedreferenceVillanueva C, Minana J, Ortiz J, et al. Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding. N Engl J Med 2001; 345: 647 – 55.en_US
dc.identifier.citedreferenceLo G-H, Chen W-C, Chen M-H, et al. Banding ligation versus nadolol and isosorbide mononitrate for the prevention of esophageal variceal rebleeding. Gastroenterology 2002; 123: 728 – 34.en_US
dc.identifier.citedreferencePatch D, Sabin CA, Goulis J, et al. A randomized, controlled trial of medical therapy versus endoscopic ligation for the prevention of variceal rebleeding in patients with cirrhosis. Gastroenterology 2002; 123: 1013 – 9.en_US
dc.identifier.citedreferencePapatheodoridis GV, Goulis J, Leandro G, et al. Transjugular intrahepatic portosystemic shunt compared with endoscopic treatment for prevention of variceal rebleeding: A meta-analysis. Hepatology 1999; 30: 612 – 22.en_US
dc.identifier.citedreferenceLo GH, Lai KH, Cheng JS, et al. Endoscopic variceal ligation plus nadolol and sucralfate compared with ligation alone for the prevention of variceal rebleeding: A prospective, randomized trial. Hepatology 2000; 32: 461 – 5.en_US
dc.identifier.citedreferencePomier-Layrargues G, Villeneuve JP, Deschenes M, et al. Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: A randomised trial. Gut 2001; 48: 390 – 6.en_US
dc.identifier.citedreferenceRusso MW, Zacks SL, Sandler RS, et al. Cost-effectiveness analysis of transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic therapy for the prevention of recurrent esophageal variceal bleeding. Hepatology 2000; 31: 358 – 63.en_US
dc.identifier.citedreferenceGatta A, Merkel C, Sacerdoti D, et al. Nadolol for prevention of variceal rebleeding in cirrhosis: A controlled clinical trial. Digestion 1987; 37: 22 – 8.en_US
dc.identifier.citedreferenceRossi V, Cales P, Burtin P, et al. Prevention of recurrent variceal bleeding in alcoholic cirrhotic patients: Prospective controlled trial of propranolol and sclerotherapy. J Hepatol 1991; 12: 283 – 9.en_US
dc.identifier.citedreferenceLebrec D, Poynard T, Hillon P, et al. Propranolol for the prevention of recurrent gastrointestinal bleeding in patients with cirrhosis. N Engl J Med 1981; 305: 1371 – 4.en_US
dc.identifier.citedreferenceBurroughs AK, Jenkins WJ, Sherlock S, et al. Controlled trial of propranolol for the prevention of recurrent variceal hemorrhage in patients with cirrhosis. N Engl J Med 1983; 309: 1539 – 42.en_US
dc.identifier.citedreferenceColombo M, De Franchis R, Tommasini M, et al. Beta-blockade prevents recurrent gastrointestinal bleeding in well-compensated patients with alcoholic cirrhosis: A multicenter randomized controlled trial. Hepatology 1989; 9: 433 – 8.en_US
dc.identifier.citedreferenceVilleneuve J-P, Pomier-Layrargues G, Infante-Rivard C, et al. Propranolol for the prevention of recurrent variceal hemorrhage: A controlled trial. Hepatology 1986; 6: 1239 – 43.en_US
dc.identifier.citedreferenceGournay J, Masliah C, Martin T, et al. Isosorbide mononitrate and propranolol compared with propranolol alone for the prevention of variceal rebleeding. Hepatology 2000; 31: 1239 – 45.en_US
dc.identifier.citedreferenceJalan R, Forrest EH, Stanley AJ, et al. A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices. Hepatology 1997; 26: 1115 – 22.en_US
dc.identifier.citedreferenceSauer P, Theilmann L, Stremmel W, et al. Transjugular intrahepatic portosystemic stent shunt versus sclerotherapy plus propranolol for variceal rebleeding. Gastroenterology 1997; 113: 1623 – 31.en_US
dc.identifier.citedreferenceGulberg V, Schepke M, Geigenberger G, et al. Transjugular intrahepatic portosystemic shunting is not superior to endoscopic variceal band ligation for prevention of variceal rebleeding in cirrhotic patients: A randomized, controlled trial. Scand J Gastroenterol 2002; 37: 338 – 43.en_US
dc.identifier.citedreferenceGold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.en_US
dc.identifier.citedreferenceCompany ME. Drug topics red book. Montvale, NJ: Medical Economics Company, 2002.en_US
dc.identifier.citedreferenceYounossi ZM, Boparai N, McCormick M, et al. Assessment of utilities and health-related quality of life in patients with chronic liver disease. Am J Gastroenterol 2001; 96: 579 – 83.en_US
dc.identifier.citedreferenceChong CAKY, Gulamhussein A, Heathcote EJ, et al. Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol 2003; 98: 630 – 8.en_US
dc.identifier.citedreferenceBennett WG, Inoue Y, Beck JR, et al. Estimates of the cost-effectiveness of a single course of interferon-alpha2b in patients with histologically mild chronic Hepatitis C. Ann Intern Med 1997; 127: 855 – 65.en_US
dc.identifier.citedreferenceWong JB, Bennett WG, Koff RS, et al. Pretreatment evaluation of chronic Hepatitis C: Risks, benefits, and costs. JAMA 1998; 280: 2088 – 93.en_US
dc.identifier.citedreferenceChapman RH, Stone PW, Sandberg EA, et al. A Comprehensive league table of cost-utility ratios and a sub-table of “panel-worthy” studies. Med Decis Making 2000; 20: 451 – 67.en_US
dc.identifier.citedreferenceKo DT, Hebert PR, Coffey CS, et al. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA 2002; 288: 351 – 7.en_US
dc.identifier.citedreferenceSonnenberg A, Inadomi JM, Bauerfeind P. Reliability block diagrams to model disease management. Med Decis Making 1999; 19: 180 – 5.en_US
dc.identifier.citedreferenceSonnenberg A, Inadomi JM. Reliability block diagrams to model the management of colorectal cancer. Dig Dis Sci 1999; 44: 314 – 21.en_US
dc.identifier.citedreferencePoynard T, Lebrec D, Hillon P, et al. Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: A prospective study of factors associated with rebleeding. Hepatology 1987; 7: 447 – 51.en_US
dc.identifier.citedreferenceLuca A, D'Amico G, La Galla R, et al. TIPS for prevention of recurrent bleeding in patients with cirrhosis: Meta-analysis of randomized clinical trials. Radiology 1999; 212: 411 – 21.en_US
dc.identifier.citedreferenceBurroughs AK, Vangeli M. Transjugular intrahepatic portosystemic shunt versus endoscopic therapy: Randomized trials for secondary prophylaxis of variceal bleeding: An updated meta-analysis. Scand J Gastroenterol 2002; 37: 249 – 52.en_US
dc.identifier.citedreferenceAndersen PK, Esbjerg S, Sorensen TI. Multi-state models for bleeding episodes and mortality in liver cirrhosis. Stat Med 2000; 19: 587 – 99.en_US
dc.identifier.citedreferenceD'Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: A meta-analytic review. Hepatology 1995; 22: 332 – 54.en_US
dc.identifier.citedreferenceRosellini SR, Miglio F. Beta-blockers for the prevention of variceal haemorrhage in patients with cirrhosis: An updated meta-analysis of randomized controlled trials. Ital J Gastroenterol 1991; 23: 408 – 15.en_US
dc.identifier.citedreferenceThomsen BL, Sorensen TIA. Project CEVS: Analysis of the treatment effect on recurrent bleeding and death in patients with cirrhosis and esophageal varices. J Hepatol 1998; 28: 107 – 14.en_US
dc.identifier.citedreferenceEscorsell A, Banares R, Garcia-Pagan JC, et al. TIPS versus drug therapy in preventing variceal rebleeding in advanced cirrhosis: A randomized controlled trial. Hepatology 2002; 35: 385 – 92.en_US
dc.identifier.citedreferenceHoyert DL, Arias E, Smith BL, et al. Deaths: Final data for 1999. Natl Vital Stat Rep 2001; 49: 1 – 114.en_US
dc.identifier.citedreferenceWiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124: 91 – 6.en_US
dc.identifier.citedreferenceLaine L, El-Newihi HM, Migikovsky B, et al. Endoscopic ligation compared with sclerotherapy for the treatment of bleeding esophageal varices. Ann Intern Med 1993; 119: 1 – 7.en_US
dc.identifier.citedreferenceSilverstein FE, Gilbert DA, Tedesco FJ, et al. The national ASGE survey on upper gastrointestinal bleeding. Gastroint Endos 1981; 27: 73 – 102.en_US
dc.identifier.citedreferenceRossle M, Siegerstetter V, Huber M, et al. The first decade of the transjugular intrahepatic portosystemic shunt (TIPS): State of the art. Liver 1998; 18: 73 – 89.en_US
dc.identifier.citedreferencePagliaro L, Burroughs AK, Sorensen TIA, et al. Therapeutic controversies and randomised controlled trials (RCTs): Prevention of bleeding and rebleeding in cirrhosis. Gastroenterol Int 1989; 2: 71 – 84.en_US
dc.identifier.citedreferenceDel Olmo JA, Pena A, Serra MA, et al. Predictors of morbidity and mortality after the first episode of upper gastrointestinal bleeding in liver cirrhosis. J Hepatol 2000; 32: 19 – 24.en_US
dc.identifier.citedreferencePagliaro L, D'Amico G, Pasta L, et al. Efficacy and efficiency of therapy in portal hypertension. In: Baveno International Consensus Workshop on Definitions M, and Therapeutic Strategies, Portal hypertension II: Proceedings of the Second Baveno International Consensus Workshop. Cambridge, MA: Blackwell Science, 1996: 159 – 79.en_US
dc.identifier.citedreferenceMorgan AG, Clamp SE. OMGE international upper gastrointestinal bleeding survey, 1978–1986. Scand J Gastroenterol 1988; 23: 51 – 8.en_US
dc.identifier.citedreferenceSanyal AJ, Freedman AM, Luketic VA, et al. Transjugular intrahepatic portosystemic shunts compared with endoscopic sclerotherapy for the prevention of recurrent variceal hemorrhage. Ann Intern Med 1997; 126: 849 – 57.en_US
dc.identifier.citedreferenceCabrera J, Maynar M, Granados R, et al. Transjugular intrahepatic portosystemic shunt versus sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology 1996; 110: 832 – 9.en_US
dc.identifier.citedreferenceRossle M, Deibert P, Haag K, et al. Randomised trial of transjugular-intrahepatic-portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding. Lancet 1997; 349: 1043 – 9.en_US
dc.identifier.citedreferenceGarcia-Villarreal L, Martinez-Lagares F, Sierra A, et al. Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal rebleeding after recent variceal hemorrhage. Hepatology 1999; 29: 27 – 32.en_US
dc.identifier.citedreferenceMerli M, Salerno F, Riggio O, et al. Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal bleeding in cirrhosis: A randomized multicenter trial. Gruppo Italiano Studio TIPS (G.I.S.T.). Hepatology 1998; 27: 48 – 53.en_US
dc.identifier.citedreferenceSauer P, Benz C, Theilman L, et al. Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: Final results of a randomized study. Gastroenterology 1998; 114: A604.en_US
dc.identifier.citedreferenceCello JP, Ring EJ, Olcott EW, et al. Endoscopic sclerotherapy compared with percutaneous transjugular intrahepatic portosystemic shunt after initial sclerotherapy in patients with acute variceal hemorrhage. Ann Intern Med 1997; 126: 858 – 65.en_US
dc.identifier.citedreferencePagliaro L, D'Amico G, Pasta L, et al. Portal hypertension in cirrhosis: Natural history. In: Groszmann RJ, ed. Portal hypertension: Pathophysiology and treatment. Boston: Blackwell Scientific, 1994: 77 – 92.en_US
dc.identifier.citedreferenceCortez-Pinto H, Abrantes A, Esteves AV, et al. Long-term prognosis of patients with cirrhosis of the liver and upper gastrointestinal bleeding. Am J Gastroenterol 1989; 84: 1239 – 43.en_US
dc.identifier.citedreferenceCooper GS, Bellamy P, Dawson NV, et al. A prognostic model for patients with end-stage liver disease. Gastroenterology 1997; 113: 1278 – 88.en_US
dc.identifier.citedreferenceSchlichting P, Christensen E, Fauerholdt L, et al. Main causes of death in cirrhosis. Scand J Gastroenterol 1983; 18: 881 – 8.en_US
dc.identifier.citedreferenceD'Amico G, Morabito A, Pagliaro L, et al. Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig Dis Sci 1986; 31: 468 – 75.en_US
dc.identifier.citedreferenceTait IS, Krige JEJ, Terblanche J. Endoscopic band ligation of oesophageal varices. Br J Surg 1999; 86: 437 – 46.en_US
dc.identifier.citedreferenceYoung MF, Sanowski RA, Rasche R. Comparison and characterization of ulcerations induced by endoscopic ligation of esophageal varices versus endoscopic sclerotherapy. Gastrointest Endosc 1993; 39: 119 – 22.en_US
dc.identifier.citedreferenceCipolletta L, Bianco MA, Rotondano G, et al. Argon plasma coagulation prevents variceal recurrence after band ligation of esophageal varices: Preliminary results of a prospective randomized trial. Gastrointest Endosc 2002; 56: 467 – 71.en_US
dc.identifier.citedreferenceHou M-C, Lin H-C, Lee F-Y, et al. Recurrence of esophageal varices following endoscopic treatment and its impact on rebleeding: Comparison of sclerotherapy and ligation. J Hepatol 2000; 32: 202 – 8.en_US
dc.identifier.citedreferenceSarin SK, Govil A, Jain AK, et al. Prospective randomized trial of endoscopic sclerotherapy versus variceal band ligation for esophageal varices: Influence on gastropathy, gastric varices and variceal recurrence. J Hepatol 1997; 26: 826 – 32.en_US
dc.identifier.citedreferenceGoff JS, Reveille RM, Stiegmann GV. Three years experience with endoscopic variceal ligation for treatment of bleeding varices. Endoscopy 1992; 24: 401 – 4.en_US
dc.identifier.citedreferenceGimson AES, Ramage JK, Panos MZ, et al. Randomised trial of variceal banding ligation versus injection sclerotherapy for bleeding oesophageal varices. Lancet 1993; 342: 391 – 4.en_US
dc.identifier.citedreferenceStiegmann GV, Goff JS, Michaletz-Onody PA, et al. Endoscopic sclerotherapy as compared with endoscopic ligation for bleeding esophageal varices. N Engl J Med 1992; 326: 1527 – 32.en_US
dc.identifier.citedreferenceLo G-H, Lai K-H, Cheng J-S, et al. A prospective, randomized trial of sclerotherapy versus ligation in the management of bleeding esophageal varices. Hepatology 1995; 22: 466 – 71.en_US
dc.identifier.citedreferenceQuine MA. Prospective audit of upper gastrointestinal endoscopy in two regions of England: Safety, staffing, and sedation methods. Gut 1995; 36: 462 – 7.en_US
dc.identifier.citedreferenceSilvis SE, Nebel O, Rogers G, et al. Endoscopic complications: Results of the 1974 American Society for Gastrointestinal Endoscopy survey. JAMA 1976; 235: 928 – 30.en_US
dc.identifier.citedreferenceArrowsmith JB, Gerstman BB, Fleischer DE, et al. Results from the American Society for Gastrointestinal Endoscopy/U.S. Food and Drug Administration collaborative study on complication rates and drug use during gastrointestinal endoscopy. Gastrointest Endosc 1991; 37: 421 – 7.en_US
dc.identifier.citedreferenceFreedman AM, Sanyal AJ, Tisnado J, et al. Complications of transjugular intrahepatic portosystemic shunt: A comprehensive review. Radiographics 1993; 13: 1185 – 210.en_US
dc.identifier.citedreferenceStanley AJ, Jalan R, Forrest EH, et al. Longterm follow up of transjugular intrahepatic portosystemic stent shunt (TIPSS) for the treatment of portal hypertension: Results in 130 patients. Gut 1996; 39: 479 – 85.en_US
dc.identifier.citedreferenceNazarian GK, Ferral H, Bjarnason H, et al. Effect of transjugular intrahepatic portosystemic shunt on quality of life. Am J Roentgenol 1996; 167: 963 – 9.en_US
dc.identifier.citedreferenceSahagun G, Benner KG, Saxon R, et al. Outcome of 100 patients after transjugular intrahepatic portosystemic shunt for variceal hemorrhage. Am J Gastroenterol 1997; 92: 1444 – 52.en_US
dc.identifier.citedreferenceSanyal AJ, Freedman AM, Luketic VA, et al. The natural history of portal hypertension after transjugular intrahepatic portosystemic shunts. Gastroenterology 1997; 112: 889 – 98.en_US
dc.identifier.citedreferenceLaBerge JM, Somberg KA, Lake JR, et al. Two-year outcome following transjugular intrahepatic portosystemic shunt for variceal bleeding: Results in 90 patients. Gastroenterology 1995; 108: 1143 – 51.en_US
dc.identifier.citedreferenceCanizares RB, Rodriguez-Laiz JM, Martin MC, et al. Transjugular intrahepatic portosystemic shunt with the Strecker stent for control of refractory acute and chronic variceal bleeding: Results in 50 patients. Scand J Gastroenterol 1996; 31: 285 – 93.en_US
dc.identifier.citedreferenceLind CD, Malisch TW, Chong WK, et al. Incidence of shunt occlusion or stenosis following transjugular intrahepatic portosystemic shunt placement. Gastroenterology 1994; 106: 1277 – 83.en_US
dc.identifier.citedreferenceRossle M, Siegerstetter V, Olschewski M, et al. How much reduction in portal pressure is necessary to prevent variceal rebleeding? A longitudinal study in 225 patients with transjugular intrahepatic portosystemic shunts. Am J Gastroenterol 2001; 96: 3379 – 83.en_US
dc.identifier.citedreferenceKanterman RY, Darcy MD, Middleton WD, et al. Doppler sonography findings associated with transjugular intrahepatic portosystemic shunt malfunction. Am J Roentgenol 1997; 168: 467 – 72.en_US
dc.identifier.citedreferenceDodd GD III, Zajko AB, Orons PD, et al. Detection of transjugular intrahepatic portosystemic shunt dysfunction: Value of duplex Doppler sonography. Am J Roentgenol 1995; 164: 1119 – 24.en_US
dc.identifier.citedreferenceChong WK, Malisch TA, Mazer MJ, et al. Transjugular intrahepatic portosystemic shunt: US assessment with maximum flow velocity. Radiology 1993; 189.en_US
dc.identifier.citedreferenceViamonte M Jr, LePage J, Lunderquist A, et al. Selective catheterization of the portal vein and its tributaries. Preliminary report. Radiology 1975; 114: 457 – 60.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1572-0241.2004.04153.x.pdf
Size:
182.1KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.